Friday, 3 July 2020
06:00 SF / 10:00 RIO / 15:00 JO’BURG / 21:00 BEIJING
OFFICIAL MEDIA ROUNDTABLE
HIV Cure Media Round Table
Media roundtable providing an opportunity for media to engage in conversation with the London Patient, only the second person to cured of HIV (34 months in remission) after a stem cell bone marrow transplant.
- (Chair) Sharon Lewin, IAS Initiative Towards an HIV Cure, Director, Peter Doherty Institute for Infection and Immunity, Melbourne , Australia
- Ravi Gupta, Professor of Clinical Microbiology, Wellcome Trust Senior Fellow in Clinical Science, University of Cambridge, UK
- London Patient, UK
- (Co-Chair) Mark Dybul, IAS Initiative Towards an HIV Cure, Co-Director of the Center for Global Health Practice and Impact, Georgetown University, Washington D.C, U.S.
Monday, 6 July 2020
07:00 SF / 11:00 RIO / 16:00 JO’BURG / 22:00 BEIJING
OFFICIAL PRESS CONFERENCE
AIDS 2020: Virtual Official Opening Press Conference
Organizer: AIDS 2020: Virtual
- (Chair) Anton Pozniak, AIDS 2020: Virtual International Scientific Chair
- Winnie Byanyima, Executive Director, UNAIDS
- Tedros Adhanom Ghebreyesus, Director General, World Health Organization
- Erik Lamontagne, Senior Economist, UNAIDS: UNAIDS: COVID-19 pandemic increases socioeconomic vulnerability of LGBTI+ communities and their susceptibility to HIV
- Douglas Krakower, Division of Infectious Diseases Faculty, Beth Israel Deaconess Medical Center; Research Scientist, The Fenway Institute; Assistant Professor in Medicine & Population Medicine, Harvard Medical School: Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center
Tuesday, 7 July 2020
05:00 SF / 09:00 RIO / 14:00 JO’BURG / 20:00 BEIJING
THIRD PARTY PRESS CONFERENCE
Launch of Start Free, Stay Free, AIDS Free
Organizer: UNAIDS
A report reviewing recent gains, new developments and remaining challenges in reducing the number of new HIV infections among children as well as increasing the number of children with HIV on treatment.
- Shannon Hader, Deputy Executive Director, UNAIDS
- Peter Ghys, Director, Strategic Information and Evaluation, UNAIDS
06:00 SF / 10:00 RIO / 15:00 JO’BURG / 21:00 BEIJING
OFFICIAL PRESS CONFERENCE
AIDS 2020: Virtual HIV Science Highlights
- (Co-Chair) Monica Gandhi, AIDS 2020: Virtual Local Co-Chair
- (Co-Chair) Cynthia Carey-Grant, AIDS 2020: Virtual Local Co-Chair
- Raphael J. Landovitz, Professor of medicine in the Division of Infectious Diseases at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), and co-director of the UCLA Center for Clinical AIDS Research & Education (CARE)
- Ricardo Diaz, Head of Retrovirology Lab & Infectious Disease Professor, Federal University of Sao Paulo: The first long-term remission of chronic HIV-1 infection without myeloablation?
- Rebecca Zash, Co-Director, Placental Scientific Working Group, Harvard University Center for AIDS Research: Update on neural tube defects with antiretroviral exposure in the Tsepamo study: Botswana
- Simiso Sokhela, EZINTSHA, University of the Witwatersrand: The ADVANCE trial: Phase 3, randomized comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection
- Catherine Koss, Assistant Professor of Medicine, University of California, San Francisco: Lower than expected HIV incidence among men and women at elevated HIV risk in a population-based PrEP study in rural Kenya and Uganda: Interim results from the SEARCH study
09:00 SF / 13:00 RIO / 18:00 JOBURG / 24:00 BEIJING
THIRD PARTY PRESS CONFERENCE
How is COVID-19 impacting services for HIV and related health areas? New data and perspectives
Organizer: World Health Organization
The COVID-19 pandemic has raised serious challenges for health services, including those related to HIV, tuberculosis, viral hepatitis and sexually transmitted infections. This press briefing will be held on 7 July, immediately after the satellite session “COVID-19 mitigation approaches for HIV, viral hepatitis and sexually transmitted infections.” Speakers will share: new data and evidence on essential service disruptions, supply chain challenges and stockouts; the findings of a new study on the associated risks and poor outcomes due to COVID among people living with HIV in South Africa; and the impact of COVID-19 on hepatitis services and achieving viral hepatitis elimination. The urgent need to strengthen access to appropriate HIV services and commodities for children in the era of COVID-19 will also be highlighted.
- Meg Doherty, Director of the Department of HIV, Hepatitis and STI programmes, WHO
- Martina Penazzato, pediatric HIV lead for the Department of HIV, Hepatitis and STI programmes, WHO
- Mary-Ann Davies, Associate Professor, School of Public Health and Family Medicine, University of Cape Town
- Salim Abdool Karim, Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA)
10:00 SF / 14:00 RIO / 19:00 JO’BURG / 01:00 BEIJING
MEDIA ROUNDTABLE
Where we are with HIV prevention research
Organizer: AVAC
The first half of 2020 has been a rollercoaster for the HIV prevention field. February brought disappointing news of the HVTN 702 vaccine efficacy study stopped early when it was determined the vaccine did not prevent HIV. In May news came that one study (HPTN083) of the long-acting injectable (LAI) drug cabotegravir for PrEP was stopped early for efficacy. A second LAI PrEP study among cisgender women in Africa is continuing, with results expected later this year or in 2021. Go behind the headlines of these dramatic trial stops and hear what these studies and other ongoing studies tell us about where we are in the search for new HIV prevention options for the people who need them most. Speakers will include top HIV prevention researchers and advocates who are working together to find new solutions.
- Linda-Gail Bekker, Past President of IAS and deputy director of the Desmond Tutu HIV Centre
- Nyaradzo Mgodi, Clinical Pathologist and Principal Investigator at the University of Zimbabwe College of Health Sciences Clinical Trials Research Centre
- Cleopatra Sheilla Makura, Youth Prevention Advocate, 2019 AVAC Advocacy Fellow
- Moderated by Manju Chatani-Gada, Director of Partnerships & Capacity Strengthening, AVAC
Wednesday, 8 July 2020
10:00 SF / 14:00 RIO / 19:00 JO’BURG / 01:00 BEIJING
THIRD PARTY PRESS CONFERENCE
Health Disparities: HIV and COVID-19
Organizer: Johnson & Johnson
Systemic racism has left people of color exposed and unprotected against global health threats, including HIV, for decades. These inequities are magnified by the disparity seen in COVID-19 health outcomes. This press conference will illuminate the deep impact systematic racism on health care and health outcomes in communities of color and actions being taken to address health inequities.
- Cato T. Laurencin, M.D., Ph.D., Physician, and professor at the University of Connecticut Health Center
- Joanne Peter, M.D., Director of Social Innovation for Johnson & Johnson Global Community Impact
- Macaya Douoguih, M.D., MPH, Head, Janssen Clinical Development and Medical Affairs, Vaccines
Thursday, 9 July, 2020
09:00 SF / 13:00 RIO / 18:00 JO’BURG / 24:00 BEIJING
OFFICIAL PRESS CONFERENCE
COVID-19 Conference Highlights
Organizer: International AIDS Society
- (Chair) Adeeba Kamarulzaman, IAS President-Elect
- Anthony Fauci, Director, National Institute of Allergy & Infectious Diseases
- Claudio Fenizia, Postdoctoral Researcher, University of Milan: In-utero mother-to-child SARS-CoV-2 transmission – viral detection and fetal immune response
- Andrew Hill, Senior visiting Research Fellow, Department of Pharmacology, Liverpool University: Sofosbuvir and daclatasvir as a potential candidate for moderate or severe COVID-19 treatment, results from a randomised clinical trial
- Kristen Marks, Physician, Weill Cornell Medicine: Baseline characteristics associated with clinical improvements and mortality in hospitalized patients with severe COVID-19 treated with remdesivir
- Carina Marquez, Assistant Professor of Medicine & Associate Director of Education, Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital; Associate Director for Equity, UCSF Center for AIDS Research: High prevalence of asymptomatic SARS-CoV-2 infection found in a Latinx population in San Francisco in a mass testing campaign
10:00 SF / 14:00 RIO / 19:00 JO’BURG / 01:00 BEIJING
MEDIA ROUNDTABLE
The COVID vaccine research enterprise
Organizer: AVAC
Confused about the COVID vaccine pipeline? Wondering which timeline for a safe, effective and approved vaccine to believe? Want to know more about how researchers are working cooperatively to dramatically – yet safely – shorten research timelines to get to vaccines that help end the COVID-19 pandemic? What about the role of community engagement and Good Participatory Practice (GPP) in COVID research. Join Mitchell Warren, AVAC executive director, in discussion with a top US government vaccine researcher and advocates to discuss the latest developments in COVID vaccine research and the way forward.